| Pack Size | Single Vial, 10-Pack |
|---|
CJC-1295 No DAC is a synthetic 29-residue growth-hormone-releasing hormone analogue derived from the parent hGHRH(1-29) with four amino-acid substitutions that confer protease resistance. The molecule is sometimes called Modified GRF(1-29) or Mod-GRF(1-29). Unlike the DAC-conjugated variant of CJC-1295, the No DAC form lacks the maleimidoproprionic-acid linker for albumin binding, giving it a substantially shorter plasma half-life. Research has investigated the compound across GH-axis pharmacology, pulsatile-GH-release characterisation, and combined GHRH-plus-GHRP studies. Every Ronin batch is independently verified by Janoshik Analytical using HPLC for purity and mass spectrometry for identity, with the minimum acceptance threshold set at 99 percent purity by HPLC. The compound is supplied as a lyophilized powder in a sealed glass vial, 10 mg per vial. For laboratory research use only — not for human or veterinary use.
Description
This compound is a synthetic 29-residue peptide whose sequence sits on the parent human growth-hormone-releasing hormone fragment hGHRH(1-29), with four amino-acid substitutions that confer enhanced plasma stability against the proteolytic enzymes that rapidly degrade native GHRH. The substitutions are at positions 2 (D-Ala for Ala — protects the N-terminus from dipeptidyl peptidase IV), position 8 (Gln for Asn — reduces deamidation), position 15 (Ala for Gly — reduces aspartic-acid attack at this site), and position 27 (Leu for Met — prevents methionine oxidation). The resulting peptide retains agonist activity at the GHRH receptor while resisting the multiple proteolytic pathways that limit native-GHRH plasma half-life.
The "No DAC" suffix distinguishes this molecule from its longer-acting sibling CJC-1295 with DAC. The DAC variant carries a maleimidoproprionic-acid linker at the C-terminus that binds covalently to plasma albumin, extending the plasma half-life from minutes to days. The No DAC form lacks this albumin-binding moiety; its plasma half-life sits in the same range as the modified parent peptide alone — approximately thirty minutes after parenteral administration in animal models. Researchers studying pulsatile GH-release dynamics often prefer the No DAC form because the shorter plasma residence allows a more native-like GH pulse pattern compared with the continuous receptor stimulation produced by the long-acting DAC variant.
The compound is supplied as a lyophilized white-to-off-white powder in a sealed amber-glass vial under inert gas. Each vial contains 10 mg of peptide. Reconstitution with bacteriostatic water is required before the peptide can be drawn into an insulin syringe. Researchers planning bench preparations should review the Reconstitution accordion below for mechanics.
CJC-1295 has been the subject of an extensive preclinical and clinical-trial-stage research literature. A 2005 paper in Endocrinology characterised the parent hGRF(1-29)-albumin bioconjugate (the predecessor to CJC-1295 with DAC) as a GRF receptor agonist on the anterior pituitary somatotroph (PMID 15817669). A 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported a Phase 1/2 trial documenting prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults (PMID 16352683). A 2006 paper in the American Journal of Physiology Endocrinology and Metabolism characterised the once-daily administration profile (PMID 16822960). A 2006 paper in the Journal of Clinical Endocrinology and Metabolism characterised that pulsatile GH secretion persisted during continuous CJC-1295 stimulation, an unexpected finding given the long-acting plasma profile of the DAC variant (PMID 17018654).
Across the literature the compound appears under several alternate identifiers. CJC-1295 was the development designation used by ConjuChem, the originating Canadian pharmaceutical company. Modified GRF(1-29), Mod-GRF(1-29), and Modified Sermorelin all refer to the No DAC form specifically. The development designation distinguishes the No DAC form (~3367 g/mol) from the DAC form (~3647 g/mol with the linker addition). Researchers should be alert to which form is being supplied and verify against the COA returned for each batch.
No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared CJC-1295 No DAC for therapeutic use in humans or animals. The compound progressed through Phase 2 trials under ConjuChem in the mid-2000s for indications including HIV-associated lipodystrophy, but did not advance to a marketed therapeutic. Ronin Peptides ships the compound exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.
Mechanism in research literature
The mechanistic anchor for CJC-1295 No DAC is agonism at the growth-hormone-releasing-hormone receptor (GHRHR), a Gs-coupled G-protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Receptor activation triggers an adenylyl-cyclase / cAMP / protein-kinase-A signalling cascade, leading to vesicular release of growth hormone from somatotroph storage pools. The GHRH receptor and the ghrelin / GHSR-1a receptor (target of Ipamorelin and other GHRPs) are distinct receptors operating through separate G-protein cascades, but converge on stimulation of GH release.
The four amino-acid substitutions distinguishing the modified parent from native hGHRH(1-29) confer plasma-stability enhancements without compromising receptor agonism. A 2005 paper in Endocrinology characterised the parent hGRF(1-29)-albumin bioconjugate as a GRF-receptor agonist (PMID 15817669). The hGRF(1-29)-albumin work led directly to the DAC variant CJC-1295 development programme; the No DAC form preserves the parent peptide's substitutions without the albumin-binding moiety.
Pharmacokinetic and pharmacodynamic characterisation of the DAC variant established the quantitative profile against which the No DAC form is interpreted. A 2006 Phase 1/2 paper in the Journal of Clinical Endocrinology and Metabolism documented prolonged GH and IGF-1 stimulation following single-dose administration of CJC-1295 (PMID 16352683). A 2006 paper in the American Journal of Physiology Endocrinology and Metabolism characterised the once-daily-administration profile in healthy adults (PMID 16822960). A 2009 paper in Growth Hormone & IGF Research documented the GH/IGF-1 axis serum protein profile under sustained CJC-1295 administration (PMID 19386527). The No DAC form, lacking albumin binding, produces a substantially shorter GH pulse profile than the DAC variant — closer to native GHRH stimulation timing.
One mechanism finding from the early CJC-1295 work has shaped subsequent GHRH-analogue research broadly: pulsatile GH secretion persists even under continuous receptor stimulation. A 2006 paper in JCEM reported that despite the long-acting plasma profile of CJC-1295 with DAC, GH release remained pulsatile, suggesting that the somatotroph itself imposes pulsatile-release dynamics independent of the temporal profile of receptor activation (PMID 17018654). The finding has implications for the broader interpretation of GHRH-axis pharmacology in research contexts.
Comparative mechanism work positions CJC-1295 against other GHRH analogues. Investigators have studied Tesamorelin (development designation TH9507) extensively. Tesamorelin is another modified GHRH analogue. It has been characterised in clinical research for HIV-associated lipodystrophy (PMID 20554713). Sermorelin is the unmodified hGHRH(1-29) parent. Its shorter plasma half-life has been documented across multiple studies. CJC-1295 No DAC sits between these two on the modified-GHRH-analogue continuum. Researchers have examined the comparative pharmacology and observed distinct GH-pulse profiles across the three molecules.
Studied properties
GH-axis pharmacology forms the foundational body of preclinical and clinical-stage research on CJC-1295. The 2006 Teichman Phase 1/2 trial paper anchored the prolonged-GH-stimulation framing (PMID 16352683). The 2006 Alba once-daily-administration paper extended the dosing-pharmacology characterisation (PMID 16822960). The 2009 Sackmann-Sala serum-protein-profile paper documented downstream IGF-1 axis effects (PMID 19386527). These three papers, alongside the foundational 2005 Jetté paper on the hGRF(1-29)-albumin parent (PMID 15817669), form the core pharmacology stream.
Pulsatile-GH-release characterisation is the second major stream. The 2006 Ionescu paper in JCEM documented that GH pulses persisted during continuous CJC-1295 stimulation (PMID 17018654). The pulsatile-release framework has subsequently shaped the broader interpretation of GHRH-receptor pharmacology in research contexts. A 2013 paper in Endocrinology used a GHRH-receptor-targeted botulinum-neurotoxin construct to characterise pulsatile GH secretion mechanisms further (PMID 23825127), broadening the receptor-mechanism understanding.
Comparative GHRH-analogue research forms a third stream. The 1997 Thorner foundational review compiled the broader GHRH and GHRP therapeutic-research framework (PMID 9238854). The 2010 Falutz paper on Tesamorelin in HIV-associated lipodystrophy provides a comparative clinical-research data point against which CJC-1295 is positioned (PMID 20554713). A 2013 review in Best Practice & Research Clinical Endocrinology and Metabolism compiled the broader GH-axis-and-aging research literature (PMID 24054930). The 2013 Endocrinology botulinum-construct paper (PMID 23825127) and the 2009 Sackmann-Sala IGF-axis paper (PMID 19386527) extend the comparative-mechanism framing into receptor-targeting and downstream-IGF analytical work.
Combined GHRH-plus-GHRP research has produced an active research stream around the pairing of CJC-1295 No DAC with the GHSR-1a agonist Ipamorelin. The mechanistic rationale is dual-receptor stimulation: GHRH receptor activation by the GHRH analogue plus ghrelin-receptor activation by the GHRP. The combined-receptor stimulation produces a distinct GH-pulse profile compared with either compound alone. Researchers studying the combined-receptor framework often use the CJC-1295 + Ipamorelin blend format for consistent ratio across experimental sessions.
Analytical-detection research has produced a dedicated literature stream around CJC-1295. A 2019 paper in Drug Testing and Analysis described an immuno-polymerase chain reaction screen for detecting CJC-1295 and other growth-hormone-releasing peptides in biological samples (PMID 30489688). A 2021 review compiled advances in the detection of GHRH synthetic analogues (PMID 34665524). A 2026 paper described nano-liquid-chromatography analytical methodology for GHRH and analogues in urine (PMID 41138283). The analytical-research stream provides important context for researchers handling the compound in regulated environments. CJC-1295 also features in recent reviews of therapeutic peptides in orthopaedic and sports-medicine research contexts (PMID 41490200).
Compound specifications
| Specification | Value |
|---|---|
| Common name | CJC-1295 No DAC |
| Alternate names | Modified GRF(1-29); Mod-GRF(1-29); Modified Sermorelin |
| Molecular formula | C152H252N44O42 |
| Molecular weight | ~3367 g/mol |
| CAS number | 446262-90-2 (Mod-GRF(1-29)) |
| Length | 29 residues with C-terminal amide cap |
| Parent peptide | hGHRH(1-29) (Sermorelin) |
| Modifications | D-Ala²; Gln⁸; Ala¹⁵; Leu²⁷ (vs native GHRH(1-29) Ala-Asn-Gly-Met) |
| Receptor target | Growth-hormone-releasing-hormone receptor (GHRHR) |
| Plasma half-life (preclinical) | ~30 minutes (parenteral, animal models) |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 10 mg peptide, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by Janoshik Analytical) |
One specification note worth flagging: CJC-1295 has two principal supply forms, and the COA returned with each batch must be verified against the form actually shipped. The No DAC form sits at approximately 3367 g/mol; the DAC form sits at approximately 3647 g/mol with the maleimidoproprionic-acid linker. Researchers integrating this compound into mass-spec-coupled protocols should verify the form against the COA returned for the specific batch in hand.
Storage and handling
Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.
Keep vials shielded from light, ideally in their original outer packaging. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands — minimise transitions between cold and ambient.
After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window for a reconstituted preparation is four to six weeks at fridge temperature. Past that window, peptide concentration drifts downward through chemical degradation pathways even though the bacteriostatic water's benzyl alcohol still suppresses microbial growth. The 0.9% benzyl alcohol holds back bacterial contamination — the dominant spoilage path — but does not arrest the slower hydrolysis, oxidation, and aggregation processes that accumulate in any aqueous peptide solution.
When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature — and use them within a few days of thaw.
The reconstituted product should be visually clear and colourless. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.
Compare with similar compounds
| Compound | Primary research area | Documented mechanism (preclinical) | Format at Ronin |
|---|---|---|---|
| CJC-1295 No DAC | GHRH-axis research; pulsatile GH release | Modified hGHRH(1-29); GHRH receptor agonist; ~30 min plasma half-life | 10 mg vial |
| Ipamorelin | GH release; ghrelin-mimetic gut motility | Selective GHSR-1a agonist; GH release without prolactin/cortisol elevation | 10 mg vial |
| CJC-1295 + Ipamorelin Blend | Combined GHRH + GHRP research | Dual-receptor stimulation: GHRH receptor + GHSR-1a receptor | 10 mg blend vial |
| Tesamorelin | GHRH-receptor research; HIV-associated lipodystrophy framing | GHRH analogue; longer-acting stabilised structure | 10 mg vial |
CJC-1295 No DAC sits within Ronin's growth-related compound category, alongside the GHRP-class Ipamorelin and the longer-acting GHRH-class Tesamorelin. The mechanistic complementarity between GHRH-class compounds (which signal through the GHRH receptor) and GHRP-class compounds like Ipamorelin (which signal through the ghrelin GHSR-1a receptor) is the rationale behind the CJC-1295 + Ipamorelin combined blend, where dual-receptor stimulation produces a different GH-release profile than either compound alone.
Reconstitution and laboratory handling
A 10 mg vial of CJC-1295 No DAC reconstituted with 2 mL of bacteriostatic water yields a final concentration of 5 mg/mL, or 5,000 mcg/mL. Other diluent volumes scale linearly: 1 mL gives 10 mg/mL, 5 mL gives 2 mg/mL.
Reconstitution procedure:
- Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures peptide at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent with no suspended particulate. If the solution is hazy or contains visible material, treat it as degraded or contaminated and discard.
For dose-volume calculations on insulin syringes, use the Ronin peptide reconstitution calculator. The calculator pre-loads CJC-1295 No DAC with default reconstitution volumes and converts target doses to U-100 syringe units automatically.
In published preclinical and clinical research on CJC-1295 (DAC variant), doses ranging from 30 to 250 micrograms per kilogram have been characterised across single-dose and multi-dose administration regimens, with subcutaneous and intravenous routes most common (PMID 16352683, PMID 16822960). The No DAC form's shorter plasma half-life means dose-frequency considerations differ substantially from the DAC variant. These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.
Frequently asked questions
What is CJC-1295 No DAC?
This compound is a synthetic 29-residue peptide whose sequence sits on the parent human growth-hormone-releasing hormone fragment hGHRH(1-29), with four amino-acid substitutions that confer enhanced plasma stability against the proteolytic enzymes that rapidly degrade native GHRH. The "No DAC" suffix distinguishes this molecule from its longer-acting sibling CJC-1295 with DAC, which carries a maleimidoproprionic-acid linker for covalent albumin binding. Without the linker, the No DAC form has a plasma half-life of approximately thirty minutes — comparable to native GHRH but with the protease-resistance modifications. Research has investigated the compound across GH-axis pharmacology and combined GHRH-plus-GHRP research streams. Ronin supplies the compound as a lyophilized vial reconstituted with bacteriostatic water at the bench. Sale is limited to laboratory research applications; human and veterinary use are excluded.
What does CJC-1295 stand for?
CJC-1295 was the development designation used by ConjuChem. ConjuChem was the originating Canadian pharmaceutical company. The company advanced the compound through Phase 2 clinical trials in the mid-2000s. The "CJC" prefix references the company name. The 1295 is a non-mechanistic numerical designation. The No DAC form is also called Modified GRF(1-29), Mod-GRF(1-29), or Modified Sermorelin. These alternate names refer to the same molecule. That molecule is the 29-residue modified parent peptide without the DAC albumin-binding moiety.
What's the difference between No DAC and DAC?
The DAC moiety is a maleimidoproprionic-acid linker positioned at the C-terminus of the modified GHRH(1-29) parent peptide. In aqueous solution, the linker forms a covalent bond with cysteine residue 34 of plasma albumin, anchoring the peptide to a long-circulating carrier protein. This effectively extends the plasma half-life from minutes (the No DAC form) to many days (the DAC form). The pharmacological consequence is a sustained GH-pulse profile under the DAC variant versus a more native-like, shorter GH-pulse pattern under the No DAC form. Research applications differ accordingly: the No DAC form is often preferred for studies that require pulsatile receptor stimulation in a temporal pattern closer to endogenous GHRH release.
What is the regulatory status of CJC-1295 No DAC?
No regulatory body — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has approved CJC-1295 No DAC as a drug for human or veterinary use. The compound progressed through Phase 2 trials under ConjuChem in the mid-2000s for indications including HIV-associated lipodystrophy, but did not advance to a marketed therapeutic in any major jurisdiction.
CJC-1295 No DAC is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. It sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics.
Ronin Peptides supplies the compound as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is CJC-1295 No DAC verified?
Each batch passes through Janoshik Analytical — an independent peptide-analytics lab — for HPLC purity quantification and MS identity confirmation, with the minimum acceptance threshold set at 99 percent purity by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com. To pull the COA covering the batch on your order, email support@roninpeptides.ca from the address used at checkout, with your order number; the typical reply turnaround is well under 24 hours. The COA reports the molecular mass measured by mass spectrometry, allowing researchers to confirm the No DAC form (~3367 g/mol) versus the DAC form (~3647 g/mol).
How does CJC-1295 No DAC differ from Ipamorelin?
CJC-1295 No DAC and Ipamorelin are two distinct classes of GH-related research compound that are often examined together. CJC-1295 No DAC is a GHRH analogue — it binds the GHRH receptor on anterior-pituitary somatotrophs, mimicking the action of endogenous GHRH. Ipamorelin is a GHRP — it signals through the GHSR-1a (ghrelin) receptor on those same somatotrophs. The two receptors operate through different intracellular signalling pathways but converge on GH release. Combined-protocol research often pairs the two compound classes — see the CJC-1295 + Ipamorelin blend for combined-compound research convenience.
How is CJC-1295 No DAC reconstituted?
The standard preparation is 2 mL of bacteriostatic water added to a 10 mg vial, producing a 5 mg/mL solution. Inject the water against the inside wall of the vial — never directly onto the lyophilized powder, which causes foaming and surface denaturation. Swirl gently or invert slowly until fully dissolved (typically 30–60 seconds). Refrigerate at 2–8 °C immediately after reconstitution. Use the Ronin reconstitution calculator for non-standard volumes or to convert target doses to insulin-syringe units.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch. COAs are not published publicly to protect supply-chain privacy and prevent competitor scraping.
References
- Thorner MO. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog Horm Res. 1997;52:215-244. PMID: 9238854
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669 | doi:10.1210/en.2004-1286
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683 | doi:10.1210/jc.2005-1536
- Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1297. PMID: 16822960 | doi:10.1152/ajpendo.00201.2006
- Ionescu M et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654 | doi:10.1210/jc.2006-1702
- Sackmann-Sala L et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527 | doi:10.1016/j.ghir.2009.03.001
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20554713 | doi:10.1210/jc.2010-0490
- Leggett J et al. GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion. Endocrinology. 2013;154(9):3305-3318. PMID: 23825127 | doi:10.1210/en.2012-2175
- Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930 | doi:10.1016/j.beem.2013.05.003
- Timms M et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth hormone secretagogues. Drug Test Anal. 2019;11(5):706-716. PMID: 30489688 | doi:10.1002/dta.2554
- Memdouh S et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. PMID: 34665524 | doi:10.1002/dta.3183
- Uçaktürk E et al. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography. J Pharm Biomed Anal. 2026. PMID: 41138283 | doi:10.1016/j.jpba.2025.117207
- Rahman OF et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 | doi:10.5435/JAAOSGlobal-D-25-00236
